Rhenium-186 hydroxyethylidenediphosphonate (186Re HEDP) for the treatment of hemophilic arthropathy: first results.

MLA

Bucerius, Jan, et al. “Rhenium-186 Hydroxyethylidenediphosphonate (186Re HEDP) for the Treatment of Hemophilic Arthropathy: First Results.” The Clinical Journal of Pain, vol. 23, no. 7, Sept. 2007, pp. 612–18. EBSCOhost, https://doi.org/10.1097/AJP.0b013e318123fd4e.

APA

Bucerius, J., Wallny, T., Brackmann, H.-H., Joe, A. Y., Roedel, R., Biersack, H.-J., & Palmedo, H. (2007). Rhenium-186 hydroxyethylidenediphosphonate (186Re HEDP) for the treatment of hemophilic arthropathy: first results. The Clinical Journal of Pain, 23(7), 612–618. https://doi.org/10.1097/AJP.0b013e318123fd4e

Chicago

Bucerius, Jan, Thomas Wallny, Hans-Hermann Brackmann, Alexius Y Joe, Roland Roedel, Hans-Jürgen Biersack, and Holger Palmedo. 2007. “Rhenium-186 Hydroxyethylidenediphosphonate (186Re HEDP) for the Treatment of Hemophilic Arthropathy: First Results.” The Clinical Journal of Pain 23 (7): 612–18. doi:10.1097/AJP.0b013e318123fd4e.